Twitxy
Saved
@BioPharmaDive's profile picture
View on X

BioPharma Dive

@BioPharmaDive

We provide in-depth insight into the most significant news and trends shaping biotech and pharma. Sign up here: dive.pub/_BD9
Washington, D.C. BioPharmaDive.com Joined July 2013
308 Following 14K Followers 18K Posts

Latest posts 5

Pinned post

BioPharma Dive @BioPharmaDive
Get the latest biotech & pharma intel in your inbox for free. Our newsletters cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships.

Sign up today: biopharmadive.com/link/6547/?utm…
www.biopharmadive.com BioPharma Dive Newsletter Sign up for BioPharma Dive: The free email newsletter covering the top news and trends for biotech and pharma industry leaders.
0 replies 0 reposts 2 likes 2.7K views View on X
BioPharma Dive @BioPharmaDive
Novartis reveals cancer cases possibly linked to gene therapy Zolgensma biopharmadive.com/news/zolgensma… $NVS @ByJonGardner
www.biopharmadive.com Novartis reveals cancer cases possibly linked to gene therapy Zolgensma The occurrence of cancer in nine recipients — two of which involved evidence that a viral delivery tool integrated into patient DNA — could raise new questions for the gene therapy field.
BioPharma Dive @BioPharmaDive
News Roundup: Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down biopharmadive.com/news/lilly-him…
www.biopharmadive.com Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.